Over 400 scientific publications now document clinical benefits of Stereotaxis robotic technology Most recent publication reviews outcomes of 1,003 consecutive robotic procedures at a single center ST. LOUIS, June 02, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced […]
Tag: Stereotaxis
Stereotaxis Reports 2019 Full Year Financial Results
ST. LOUIS, March 10, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2019. “The past year was transformative for Stereotaxis with significant progress financially, commercially and […]
Stereotaxis Earns FDA Clearance and Announces U.S. Launch of Genesis Robotic Magnetic Navigation System
ST. LOUIS, March 06, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Genesis RMN® System for the robotic navigation of magnetic ablation catheters to treat heart […]
Stereotaxis to Ring the Opening Bell® of the New York Stock Exchange
ST. LOUIS, Jan. 16, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that David Fischel, Chairman and CEO, will ring the Opening Bell® of the New York Stock Exchange on Tuesday, January 21, 2020 to celebrate Stereotaxis’ positive impact […]
First Patients Treated in New Robotic Arrhythmia Care Program at Overland Park Regional Medical Center
ST. LOUIS, Dec. 16, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that HCA Midwest Health—the largest healthcare system in the Kansas City region—has launched a new robotic arrhythmia care program based at Overland Park Regional Medical Center […]
Stereotaxis CEO to Present at the 12th Annual BIOMEDevice San Jose Conference
Conference Focuses on Role of Digital Technology in Healthcare; David Fischel Named Panelist in Robotics Session ST. LOUIS, Nov. 22, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today its Chairman and Chief Executive Officer, David Fischel, will present […]
Stereotaxis Reports 2019 Third Quarter Financial Results
ST. LOUIS, Nov. 14, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2019. “The third quarter was highlighted by successful reengagement with the capital markets, meaningful progress in our […]
Stereotaxis and Catheter Precision Combine Robotic Navigation and Preoperative Arrhythmia Localization to Treat Cardiac Arrhythmias
ST. LOUIS and MT. OLIVE, N.J., Nov. 08, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE American: STXS) and Catheter Precision today announced the first patients have been successfully treated with the integration of Catheter Precision’s VIVO™ arrhythmia localization and Stereotaxis’ Robotic Magnetic Navigation technologies. VIVO uses information commonly collected prior to cardiac procedures to identify […]
Stereotaxis and inHEART Combine Robotic Precision and Advanced Preoperative 3D Mapping to Treat Cardiac Arrhythmias
ST. LOUIS and PESSAC, France, Nov. 05, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the integration of inHEART’s advanced preoperative mapping and Stereotaxis’ Robotic Magnetic Navigation technologies. inHEART applies advanced algorithms on preoperative CT and MRI images to generate highly detailed […]
Stereotaxis and ADAS 3D Combine Robotic Precision and Advanced Preoperative Substrate Mapping to Treat Cardiac Arrhythmias
ST. LOUIS and BARCELONA, Spain, Nov. 01, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL today announced the first patients have been successfully treated with the integration of ADAS 3D’s advanced preoperative substrate mapping and Stereotaxis’ Robotic Magnetic Navigation technologies. ADAS 3D helps identify possible sources of dangerous irregular heartbeats and […]
Recent
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
Bunkerhill Health and Cleerly Announce Strategic Partnership to Advance Noninvasive Cardiovascular Care
Popular
- No commented posts yet